Solid Biosciences LLC (SLDB) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US83422E1055
Gene Therapies, Cardiac Treatments, Muscular Dystrophy Drugs
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. Web URL: https://www.solidbio.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
SLDB Stock Overview
Market Cap in USD | 328m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2018-01-26 |
SLDB Stock Ratings
Growth 5y | -4.54 |
Fundamental | -63.1 |
Dividend | - |
Rel. Performance vs Sector | 3.83 |
Analysts | 4.30/5 |
Fair Price Momentum | 10.13 USD |
Fair Price DCF | - |
SLDB Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
SLDB Growth Ratios
Growth 12m | 57.56% |
Growth Correlation 12m | 32% |
Growth Correlation 3m | -13% |
CAGR 5y | -35.51% |
CAGR/Mean DD 5y | -0.46 |
Sharpe Ratio 12m | 0.45 |
Alpha vs SP500 12m | 27.88 |
Beta vs SP500 5y weekly | 1.01 |
ValueRay RSI | 48.01 |
Volatility GJR Garch 1y | 103.24% |
Price / SMA 50 | -12.07% |
Price / SMA 200 | 54.05% |
Current Volume | 68.3k |
Average Volume 20d | 193.7k |
External Links for SLDB Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of SLDB stocks?
As of May 16, 2024, the stock is trading at USD 9.69 with a total of 68,343 shares traded.
Over the past week, the price has changed by -5.46%, over one month by -3.10%, over three months by -1.42% and over the past year by +55.04%.
As of May 16, 2024, the stock is trading at USD 9.69 with a total of 68,343 shares traded.
Over the past week, the price has changed by -5.46%, over one month by -3.10%, over three months by -1.42% and over the past year by +55.04%.
What is the forecast for SLDB stock price target?
According to ValueRays Forecast Model, SLDB Solid Biosciences LLC will be worth about 11.2 in May 2025. The stock is currently trading at 9.69. This means that the stock has a potential upside of +15.89%.
According to ValueRays Forecast Model, SLDB Solid Biosciences LLC will be worth about 11.2 in May 2025. The stock is currently trading at 9.69. This means that the stock has a potential upside of +15.89%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 17 | 75.4 |
Analysts Target Price | 6.8 | -30.3 |
ValueRay Target Price | 11.2 | 15.9 |